PTGX — Protagonist Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $2.09bn
- $1.76bn
- $60.00m
- 58
- 52
- 99
- 79
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.231 | 28.6 | 27.4 | 26.6 | 60 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 80.8 | 93.7 | 153 | 158 | 154 |
Operating Profit | -80.5 | -65.1 | -126 | -131 | -93.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -77.9 | -64.8 | -126 | -127 | -79 |
Provision for Income Taxes | |||||
Net Income After Taxes | -77.2 | -66.2 | -126 | -127 | -79 |
Net Income Before Extraordinary Items | |||||
Net Income | -77.2 | -66.2 | -126 | -127 | -79 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -77.2 | -66.2 | -126 | -127 | -79 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.98 | -1.91 | -2.71 | -2.6 | -1.39 |